Magazine Article | December 1, 2023

Moving Beyond AAV: The Next Generation Of Vectors In CGT

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Adeno-associated virus (AAV) vectors are a proven, valuable tool in both research and clinical applications, but improving upon other existing vectors and developing new ones could drastically change the cell and gene therapy (CGT) landscape in 2024 and beyond.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: